Detailed narrative
ITC Matter and Remediation Plan
The International Trade Commission (ITC) issued a final determination finding a violation of Section 337 regarding two Sun Pharmaceutical patents covering components of the RhodoLED XL lamp. This resulted in a limited exclusion order and cease and desist orders, effective July 7, preventing the import or sale of the current RhodoLED XL lamp and restricting Ameluz sales for use with it. The company recorded approximately $500,000 in Q1 FY26 as an estimate for remediation costs. Biofrontera is implementing a remediation plan involving minor changes to the XL lamp to operate outside the scope of the patents, which has received FDA approval via a CBE-30 process, and is awaiting border control agreement. The company retains the right to appeal the ITC decision to the Federal Circuit.
Strategic Transaction Impact on Gross Margin
The strategic transaction completed in October 2025, which gave Biofrontera full ownership and control of all U.S. rights, approvals, and patents for the Ameluz and RhodoLED portfolio, significantly improved the company's gross margin. This transaction replaced a prior transfer pricing model of 25% to 35% of revenue with a 12% earn-out on net sales, contributing to the gross margin expansion from approximately 71% in Q2 FY25 to 80% in Q2 FY26.
Commercial Execution and Customer Dynamics
Commercial execution showed significant traction, with order count up 18.6% and average tubes per order up 10% in H1 FY26 compared to H1 FY25. Over 81% of large customers who made purchases prior to the Q4 2025 price increase placed additional orders in H1 FY26, with their Ameluz volume increasing by 41%. New account additions were 66 in H1 FY26, a slight dip from 69 in H1 FY25, attributed to focus on existing XL customers prior to ITC orders. Inside sales efforts generated approximately 1,070 tubes of Ameluz from whitespace and smaller accounts, and another 920 tubes from covering vacant territories in H1 FY26.
Clinical Pipeline as Future Growth Driver
The company's growth strategy for 2027 and beyond is centered on expanding approved uses for Ameluz through its clinical pipeline. This includes the expected launch of Ameluz PDT for superficial basal cell carcinoma in Q1 2027, anticipated FDA approval for actinic keratosis label extensions to extremities, neck, and trunk in Q3 2027, and the advancement of an acne program towards Phase III. These new indications are designed to leverage the existing installed lamp base, customer base, and sales force, minimizing additional infrastructure costs.